ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis

被引：9

作者：

Jin, Jing ^{[1
]}

Zhong, Xiao-bo ^{[1
]}

机构：

[1] Univ Connecticut, Sch Pharm, Dept Pharmaceut Sci, Storrs, CT 06269 USA

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2023年 / 44卷 / 12期

基金：

美国国家卫生研究院;

关键词：

ANTISENSE OLIGONUCLEOTIDE TOFERSEN; TRIAL;

D O I：

10.1016/j.tips.2023.08.008

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：1043 / 1044

页数：2

共 7 条

[1] Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
Benatar, Michael
Wuu, Joanne
Andersen, Peter M.
Bucelli, Robert C.
Andrews, Jinsy A.
Otto, Markus
Farahany, Nita A.
Harrington, Elizabeth A.
Chen, Weiping
Mitchell, Adele A.
Ferguson, Toby
Chew, Sheena
Gedney, Liz
Oakley, Sue
Heo, Jeong
Chary, Sowmya
Fanning, Laura
Graham, Danielle
Sun, Peng
Liu, Yingying
Wong, Janice
Fradette, Stephanie
[J]. NEUROTHERAPEUTICS, 2022, 19 (04) : 1248 - 1258
[2] Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, Karishma
Bechtold, Clara
Quijano, Elias
Ha Pham
Gupta, Anisha
Vikram, Ajit
Bahal, Raman
[J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06)
[3] Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice
Meyer, Thomas
Schumann, Peggy
Weydt, Patrick
Petri, Susanne
Koc, Yasemin
Spittel, Susanne
Bernsen, Sarah
Guenther, Rene
Weishaupt, Jochen H.
Dreger, Marie
Kolzarek, Felix
Kettemann, Dagmar
Norden, Jenny
Boentert, Matthias
Vidovic, Maximilian
Meisel, Christian
Muench, Christoph
Maier, Andre
Koertvelyessy, Peter
[J]. MUSCLE & NERVE, 2023, 67 (06) : 515 - 521
[4] Special Section on Pharmacokinetics and ADME of Biological Therapeutics-Minireview Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs
Migliorati, Julia M.
Liu, Sunna
Liu, Anna
Gogate, Anagha
Nair, Sreenidhi
Bahal, Raman
Rasmussen, Theodore P.
Manautou, Jose E.
Zhong, Xiao-bo
[J]. DRUG METABOLISM AND DISPOSITION, 2022, 50 (06) : 888 - 897
[5] Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Miller, Timothy
Cudkowicz, Merit
Shaw, Pamela J.
Andersen, Peter M.
Atassi, Nazem
Bucelli, Robert C.
Genge, Angela
Glass, Jonathan
Ladha, Shafeeq
Ludolph, Albert L.
Maragakis, Nicholas J.
McDermott, Christopher J.
Pestronk, Alan
Ravits, John
Salachas, Francois
Trudell, Randall
Van Damme, Philip
Zinman, Lorne
Bennett, C. Frank
Lane, Roger
Sandrock, Alfred
Runz, Heiko
Graham, Danielle
Houshyar, Hani
McCampbell, Alexander
Nestorov, Ivan
Chang, Ih
McNeill, Manjit
Fanning, Laura
Fradette, Stephanie
Ferguson, Toby A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (02) : 109 - 119
[6] Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Miller, Timothy M.
Cudkowicz, Merit E.
Genge, Angela
Shaw, Pamela J.
Sobue, Gen
Bucelli, Robert C.
Chio, Adriano
Van Damme, Philip
Ludolph, Albert C.
Glass, Jonathan D.
Andrews, Jinsy A.
Babu, Suma
Benatar, Michael
McDermott, Christopher J.
Cochrane, Thos
Chary, Sowmya
Chew, Sheena
Zhu, Han
Wu, Fan
Nestorov, Ivan
Graham, Danielle
Sun, Peng
McNeill, Manjit
Fanning, Laura
Ferguson, Toby A.
Fradette, Stephanie
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12) : 1099 - 1110
[7] A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration
Monine, Michael
Norris, Daniel
Wang, Yanfeng
Nestorov, Ivan
[J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2021, 48 (05) : 639 - 654

← 1 →